Exploring Undervalued Stocks On KRX With Intrinsic Value Discounts Ranging From 12.7 percent To 46.1 percent - Simply Wall St
| 326030 Stock | 103,800 500.00 0.48% |
About 53% of Sk Biopharmaceutica's investor base is interested to short. The analysis of current outlook of investing in Sk Biopharmaceuticals Co suggests that many traders are impartial regarding Sk Biopharmaceutica's prospects. The current market sentiment, together with Sk Biopharmaceutica's historical and current headlines, can help investors time the market. In addition, many technical investors use Sk Biopharmaceuticals stock news signals to limit their universe of possible portfolio assets.
326030 |
Exploring Undervalued Stocks On KRX With Intrinsic Value Discounts Ranging From 12.7 percent To 46.1 Simply Wall St
Read at news.google.com
 |
Sk Biopharmaceutica Fundamental Analysis
We analyze Sk Biopharmaceutica's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sk Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sk Biopharmaceutica based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Sk Biopharmaceutica is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Sk Biopharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sk Biopharmaceutica stock to make a market-neutral strategy. Peer analysis of Sk Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Sk Biopharmaceutica by comparing valuation metrics with similar companies.
Peers
Sk Biopharmaceutica Related Equities
| 036120 | SCI Information | 4.09 | ||||
| 092300 | Hyunwoo Industrial | 0.19 | ||||
| 058470 | LEENO Industrial | 0.05 | ||||
| 010280 | Ssangyong Information | 0.47 | ||||
| 049720 | Koryo Credit | 0.88 | ||||
| 039740 | Korea Information | 1.85 | ||||
| 030190 | NICE Information | 2.05 | ||||
| 034810 | Haesung Industrial | 2.72 |
Complementary Tools for 326030 Stock analysis
When running Sk Biopharmaceutica's price analysis, check to measure Sk Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sk Biopharmaceutica is operating at the current time. Most of Sk Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sk Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sk Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sk Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |